Latest news with #DrAgarwal
Hans India
18-07-2025
- Business
- Hans India
Temasek, others can invest more if the ecosystem is conducive
The announcement by Temasek Holdings that it intends to deploy $3 billion-4 billion annually in India is good news, especially against the backdrop of less-than-desirable foreign direct investment (FDI) that we get. Net FDI, for instance, had a steep fall of over 96 per cent, to just $353 million, in 2024-25. There was recovery too, though, as in April received net FDI of $3.95 billion, the most in 35 months. The exposure of Singapore's sovereign wealth fund to India has increased to over $50 billion, as of March this year, up from $37 billion a year earlier. In March, Temasek picked up a 10 per cent stake in Haldiram's at a valuation of around $10 billion, which was termed as a 'prized asset.' 'We've been very active in investing behind family-run businesses, we can invest across the value chain,' Vishesh Shrivastav, managing director of Temasek's India investment team, said in a media interview. Earlier, Temasek invested in many family businesses in India, such as Manipal Hospitals and Dr Agarwal's Health Care. Temasek and other investors can become more bullish about India if our policy makers get their act together. To be sure, investors are closely watching India, which is widely regarded as one of the most promising emerging markets. With a large domestic market, a young and growing population, a thriving services sector, and increasing digital penetration, India offers tremendous potential for high returns over the long term. However, this optimism is often tempered by concerns over policy inconsistency, regulatory unpredictability, and bureaucratic inefficiencies. If Indian policymakers can address these challenges with clarity, consistency, and foresight, institutional investors like Temasek may significantly ramp up their commitments. Temasek has already invested in sectors such as financial services, technology, and healthcare in India. Yet, its future decisions will be influenced by the ease with which it can navigate India's regulatory environment, repatriate profits, and find long-term policy stability. A proactive policy framework, free of sudden reversals or overregulation, would send a strong signal of reliability. For instance, India's ongoing tax disputes and retrospective taxation policies have, in the past, deterred many investors. While some steps have been taken to reverse such measures, greater transparency and policy continuity are needed to rebuild long-term trust. Additionally, infrastructure bottlenecks, delays in project clearances, and land acquisition hurdles are key concerns. If the government expedites structural reforms—such as simplifying labour laws, digitising approval processes, and strengthening contract enforcement—it would greatly enhance the investment climate. Investors are also seeking greater alignment between central and state policies, as contradictions and delays in implementation at the state level can hamper project execution. Moreover, geopolitical tensions and trade dynamics increasingly factor into capital flows. With global investors diversifying away from China, India stands to benefit—but only if it positions itself as a stable and reform-oriented alternative. Clear communication from policymakers, timely execution of flagship initiatives like Make in India and Digital India, and consistency in environmental and ESG-related norms will help boost investor confidence. Temasek and other institutional investors are not just looking for growth—they are looking for predictable, rules-based systems where they can make long-term bets without fear of regulatory shocks. If Indian policymakers can deliver on this front, India could attract not just higher investment volumes but also longer-term, strategic capital, thus driving deeper transformation across its economy.
&w=3840&q=100)
Business Standard
14-07-2025
- Business
- Business Standard
Temasek looks to invest more in family-run businesses after Haldiram's deal
Singapore's state investor Temasek is looking to invest more in Indian family-run businesses, a top executive said on Monday, months after it invested $1 billion in a popular domestic snacks company. Family businesses in India, with their multigenerational legacies, strong domestic brands and loyal customers, have become attractive for global investors in recent years. In March, Temasek bought a 10% stake in Haldiram's at a valuation of around $10 billion, with sources describing it as a "prized asset" that will help investors expand its focus on India's consumer sector. "We've been very active in investing behind family-run businesses, we can invest across the value chain," Vishesh Shrivastav, managing director of Temasek's India investment team, said in an interview at its Mumbai office. Temasek has earlier invested in many businesses in India which were once run by business families, such as Manipal Hospitals and Dr Agarwal's Health Care. In a separate factsheet, Temasek said it was "keen to partner more family-owned businesses to drive long-term value creation." It did not name any potential targets. Temasek spent $2 billion in April 2023 to raise its stake in Manipal to 59% from 18% in the biggest hospital sector deal ever in India. It later sold a minority stake to Novo Nordisk's parent Novo Holdings and Abu Dhabi's sovereign investor Mubadala, but retained majority control of the hospital chain. Asked about Manipal Hospitals possible public offering, Shrivastav said it was "an eminently listable company," without elaborating. India continues to be Temasek's best-performing market over the last decade, as it remained the world's fastest-growing major economy and the second largest IPO market in 2025. Temasek said it maintained its positive outlook for India and its 2023 goal of investing up to $10 billion in Asia's third-largest economy over a three-year horizon. Temasek invested over $3 billion in India over the past year.
Time of India
14-07-2025
- Business
- Time of India
Temasek eyes more Indian family-run businesses after Haldiram's deal
Academy Empower your mind, elevate your skills Singapore's state investor Temasek is looking to invest more in Indian family-run businesses , a top executive said on Monday, months after it invested $1 billion in a popular domestic snacks businesses in India, with their multigenerational legacies, strong domestic brands and loyal customers, have become attractive for global investors in recent March, Temasek bought a 10% stake in Haldiram's at a valuation of around $10 billion, with sources describing it as a "prized asset" that will help investors expand its focus on India's consumer sector."We've been very active in investing behind family-run businesses, we can invest across the value chain," Vishesh Shrivastav, managing director of Temasek's India investment team, said in an interview at its Mumbai has earlier invested in many businesses in India which were once run by business families, such as Manipal Hospitals and Dr Agarwal's Health a separate factsheet, Temasek said it was "keen to partner more family-owned businesses to drive long-term value creation ." It did not name any potential spent $2 billion in April 2023 to raise its stake in Manipal to 59% from 18% in the biggest hospital sector deal ever in India. It later sold a minority stake to Novo Nordisk's parent Novo Holdings and Abu Dhabi's sovereign investor Mubadala, but retained majority control of the hospital about Manipal Hospitals possible public offering, Shrivastav said it was "an eminently listable company," without continues to be Temasek's best-performing market over the last decade, as it remained the world's fastest-growing major economy and the second largest IPO market in said it maintained its positive outlook for India and its 2023 goal of investing up to $10 billion in Asia's third-largest economy over a three-year horizon. Temasek invested over $3 billion in India over the past year.
Business Times
14-07-2025
- Business
- Business Times
Temasek eyes more Indian family-run businesses after Haldiram's deal
[MUMBAI] Singapore's state investor Temasek is looking to invest more in Indian family-run businesses, a top executive said on Monday (Jul 14), months after it invested US$1 billion in a popular domestic snacks company. Family businesses in India, with their multigenerational legacies, strong domestic brands and loyal customers, have become attractive for global investors in recent years. In March, Temasek bought a 10 per cent stake in Haldiram's at a valuation of around US$10 billion, with sources describing it as a 'prized asset' that will help investors expand its focus on India's consumer sector. 'We've been very active in investing behind family-run businesses, we can invest across the value chain,' Vishesh Shrivastav, managing director of Temasek's India investment team, said in an interview at its Mumbai office. Temasek has earlier invested in many businesses in India which were once run by business families, such as Manipal Hospitals and Dr Agarwal's Health Care. In a separate factsheet, Temasek said it was 'keen to partner more family-owned businesses to drive long-term value creation.' It did not name any potential targets. Temasek spent US$2 billion in April 2023 to raise its stake in Manipal to 59 per cent from 18 per cent in the biggest hospital sector deal ever in India. It later sold a minority stake to Novo Nordisk's parent Novo Holdings and Abu Dhabi's sovereign investor Mubadala, but retained majority control of the hospital chain. Asked about Manipal Hospitals possible public offering, Shrivastav said it was 'an eminently listable company,' without elaborating. India continues to be Temasek's best-performing market over the last decade, as it remained the world's fastest-growing major economy and the second largest IPO market in 2025. Temasek said it maintained its positive outlook for India and its 2023 goal of investing up to US$10 billion in Asia's third-largest economy over a three-year horizon. Temasek invested over US$3 billion in India over the past year. REUTERS
Economic Times
22-04-2025
- Business
- Economic Times
Kotak Equities initiates coverage on Dr Agarwal's Health Care shares with add rating, foresees 8% upside
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Kotak Institutional Equities initiated coverage on Dr Agarwal's Health Care with an 'Add' rating and a target price of Rs 425, citing strong expected earnings growth and improving return ratios as the company focuses on organic expansion and operational target price implies a 7.6% potential upside from the stock's closing price of Rs 394.95 on Tuesday. Shares of Dr Agarwal's ended 1.94% lower on the largest eye care chain, Dr Agarwal's Health Care , is expected to deliver 23% and 27% compound annual growth in EBITDA and earnings per share, respectively, over FY2024–28, the brokerage said in a note. Kotak Equities forecasts 22% revenue CAGR over the same period, supported by increasing footfalls, price hikes and a continued rollout of new brokerage said it expects Dr Agarwal's return on invested capital to improve to about 12% by FY2028, from 6.6% in FY2024, driven by a more disciplined acquisition strategy and operational Chennai-based firm plans to nearly double its network to 500 centers by FY2030 from 221 locations across India and Africa as of 9MFY25. However, the brokerage said it expects over 80% of future expansion to be organic, in contrast to its previous heavy reliance on acquisitions. The company has added over 50% of its centers through M&A in the past three years, often at valuations 2–3 times higher than greenfield setups, which weighed on its return the recently added centers will continue to ramp up, the new organic additions are expected to drive growth with limited margin impact, the brokerage said, projecting EBITDA margins to rise by 80 basis points to 28% in company's hub-and-spoke model — comprising tertiary, secondary and primary centers — supports cost efficiency and scalability, the brokerage said. It expects footfalls to grow at a 22% CAGR through FY2028, aided by a cluster-based expansion strategy and capital-efficient setup model. Dr Agarwal's asset-light approach, with nearly all facilities leased, allows it to scale with minimal upfront investment, Kotak the optimistic outlook, the brokerage flagged risks such as high revenue concentration in South India, potential issues in integrating acquisitions, and promoter family read | Dr Agarwal's Health Care shares list flat at Rs 397 on BSE (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
